Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Blood (2019) 134 (Supplement_1): 557.

https://doi.org/10.1182/blood-2019-122546

Published: 2019

Journal Articles

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

Blood (2019) 134 (11): 867–879.

https://doi.org/10.1182/blood.2019000611

Published: 2019

Includes: Supplemental data

Journal Articles

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Blood (2018) 132 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2018-99-115318

Published: 2018

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

Journal Articles

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Blood (2018) 132 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2018-99-119974

Published: 2018

Journal Articles

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

Jason R. Gotlib, MDMS, Deepti Radia, MD, Daniel J. DeAngelo, MD, Prithviraj Bose, MD, Mark W Drummond, PhDMD, Elizabeth O. Hexner, MDMS, William A Robinson, MD PhD, Maureen G. Conlan, MD, Ronny G. Oren, MS, Hongliang Shi, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 351.

https://doi.org/10.1182/blood-2018-99-112017

Published: 2018

Journal Articles

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srdan Verstovsek, MD PhD, Robert P. Hasserjian, MD, Olga Pozdnyakova, MD PhD, Ivo Veletic, MD, Ruben A. Mesa, MD, Lynda Foltz, MD FRCPC, John Mascarenhas, MD, Ellen K. Ritchie, MD, Jeanne Palmer, MD, Richard T. Silver, MD, Marina Kremyanskaya, MD PhD, Bernt van den Blink, MD PhD, Renu Gupta, MD, Taghi Manshouri, PhD, C. Cameron Yin, MD PhD, Zeev E. Estrov, MD, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 686.

https://doi.org/10.1182/blood-2018-99-115362

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin

Asiri Ediriwickrema, MD, Daniel J. DeAngelo, MD, Tracy I. George, MD, Yael Rosenberg-Hasson, Cecelia Perkins, Cheryl Langford, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2018-99-117689

Published: 2018

Journal Articles

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

Kamal Menghrajani, MD, Philip S. Boonstra, PhD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Ruben A. Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz, MD

Blood (2016) 128 (22): 4270.

https://doi.org/10.1182/blood.V128.22.4270.4270

Published: 2016

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California

Oyebimpe O Adesina, MD, Ann M Brunson, MS, Jason R. Gotlib, MD, Theresa Keegan, PhD MS, Ted Wun, MD

Blood (2016) 128 (22): 2489.

https://doi.org/10.1182/blood.V128.22.2489.2489

Published: 2016

Journal Articles

Identification of a Novel MPL Loss of Function Mutation in a Patient with Cyclic Thrombocytopenia and Characterization of This Syndrome

Haiyu Zhang, PhD, Yu Hou, MD, Rondeep S. Brar, MD, Bing Zhang, MD MS, Zhenping Chen, PhD MD, Parveen Abidi, PhD, Jing Jin, MD, Jason R. Gotlib, MD, James L. Zehnder, MD

Blood (2016) 128 (22): 1376.

https://doi.org/10.1182/blood.V128.22.1376.1376

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3110.

https://doi.org/10.1182/blood.V128.22.3110.3110

Published: 2016

Journal Articles

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ronald Paquette, MD, Jason R. Gotlib, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Peter Langmuir, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3118.

https://doi.org/10.1182/blood.V128.22.3118.3118

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD, Lynda M Foltz, MD, Vikas Gupta, MD FRCP, FRCPath, John O Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD PhD, Robert P Hasserjian, MD, Elizabeth Trehu, MD, Hagop M. Kantarjian, MD, Jason R. Gotlib, MD

Blood (2014) 124 (21): 713.

https://doi.org/10.1182/blood.V124.21.713.713

Published: 2014

Journal Articles

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

Clinton C. Mason, PhD, Jamshid S. Khorashad, MD PhD, Srinivas K. Tantravahi, MD, Todd W. Kelley, MD, Anthony D. Pomicter, M.S., Anthony J. Iovino, Kimberly R. Reynolds, M.S., Anna M. Eiring, PhD, Matthew S. Zabriskie, BS, Zev Kronenberg, Jeffrey W. Tyner, Brian Dalley, PhD, Kim-Hien T. Dao, DO,PhD, Thomas O'Hare, PhD, Mark Yandell, PhD, Brian J. Druker, Jason R. Gotlib, MD, Michael W. Deininger

Blood (2014) 124 (21): 4637.

https://doi.org/10.1182/blood.V124.21.4637.4637

Published: 2014

Journal Articles

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Menghrajani Kamal, MD, Philip S. Boonstra, PhD, Alissa A. Weber, MD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Huong (Marie) Nguyen, MD, Ruben Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz

Blood (2014) 124 (21): 1842.

https://doi.org/10.1182/blood.V124.21.1842.1842

Published: 2014

NARROW

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California

Identification of a Novel MPL Loss of Function Mutation in a Patient with Cyclic Thrombocytopenia and Characterization of This Syndrome

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only